Michael Paley is a Rheumatology/Immunology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Rheumatology, Ste 5c
Saint Louis, MO 631101032
Telephone
314-286-2635Registry record last updated 17 Apr 2025.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NOVARTIS PHARMACEUTICALS CORPORATIONProgram year20251 payment
- Amgen Inc.Program year20251 payment
- UCB, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.4%Folate Analog Metabolic Inhibitor41.3%Methotrexate100%Part D≥22 patientsAntirheumatic Agent14.1%Leflunomide100%Part D<11 patientsMetabolism & gastrointestinal
26.1%Antidiarrheal microorganisms15.2%Folic Acid100%Part D<11 patientsCorticosteroid10.9%Prednisone100%Part D<11 patientsAntiparasitic
18.5%Antimalarial18.5%Hydroxychloroquine Sulfate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Identification of Pathogenic T cells in Axial Spondyloarthritis
Washington University
FY2026$154,776K08AR079593 - Identification of Pathogenic T cells in Axial Spondyloarthritis
Washington University
FY2025$154,776K08AR079593 - Identification of Pathogenic T cells in Axial Spondyloarthritis
Washington University
FY2025$649K08AR079593
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”